Physician profile

Angel Reinaldo Castro

Internal Medicine · Miami, FL

NPI 1275142176

$728.87

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$499.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $244.47 2022-2024 Micra, Evera Mri Xt Dr Surescan
Boston Scientific Corporation $174.41 2024 Watchman Flx
Takeda Pharmaceuticals U.S.A., INC. $125.06 2022
Janssen Pharmaceuticals, INC $56.33 2021-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $41.06 2024 Lifevest
Pfizer INC. $38.54 2024
Astrazeneca Pharmaceuticals LP $32.00 2023 Farxiga
Abbvie INC. $17.00 2023 Skyrizi

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Angel Reinaldo Castro

$728.87

in general payments reported 2019-2025

Years
2021-2024
Top company
Medtronic, INC.

https://glasscript.com/doctor/7920107/angel-reinaldo-castro

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.